Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics
Intellia Therapeutics, Inc. (NTLA)
Today's Latest Price: $74.36 USD
Updated Jan 22 4:00pm
Add NTLA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
NTLA Stock Summary
- With a price/sales ratio of 68.8, Intellia Therapeutics Inc has a higher such ratio than 95.42% of stocks in our set.
- Revenue growth over the past 12 months for Intellia Therapeutics Inc comes in at 55.66%, a number that bests 90.66% of the US stocks we're tracking.
- The volatility of Intellia Therapeutics Inc's share price is greater than that of 95.51% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Intellia Therapeutics Inc are KALV, MTEM, CRBP, NXTC, and DTIL.
- Visit NTLA's SEC page to see the company's official filings. To visit the company's web site, go to www.intelliatx.com.
NTLA Stock Price Chart Interactive Chart >
NTLA Price/Volume Stats
| Current price | $74.36 | 52-week high | $92.00 |
| Prev. close | $72.59 | 52-week low | $9.18 |
| Day low | $70.33 | Volume | 1,961,800 |
| Day high | $75.69 | Avg. volume | 2,003,157 |
| 50-day MA | $53.57 | Dividend yield | N/A |
| 200-day MA | $28.55 | Market Cap | 4.39B |
Intellia Therapeutics, Inc. (NTLA) Company Bio
Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Loading social stream, please wait...